Analyst Price Targets — KZIA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 9:00 am | — | Laidlaw | $25.00 | $9.46 | TheFly | Kazia Therapeutics initiated with a Buy at Laidlaw |
| December 12, 2025 11:09 am | — | H.C. Wainwright | $18.00 | $13.09 | TheFly | Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright |
| October 2, 2025 1:01 pm | — | Maxim Group | $20.00 | $6.84 | TheFly | Kazia Therapeutics price target raised to $20 from $15 at Maxim |
Latest News for KZIA
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1…
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The platform includes use of an AI-integrated epigenetic drug discovery engine, enabling…
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KZIA.
U.S. House Trading
No House trades found for KZIA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.